Key statistics
On Wednesday, Pharming Group NV (0QCO:LSE) closed at 1.34, -26.82% below its 52-week high of 1.83, set on Jan 28, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.37 |
|---|---|
| High | 1.34 |
| Low | 1.34 |
| Bid | 1.29 |
| Offer | 1.36 |
| Previous close | 1.38 |
| Average volume | 493.17k |
|---|---|
| Shares outstanding | 701.40m |
| Free float | 693.01m |
| P/E (TTM) | 399.83 |
| Market cap | 959.65m EUR |
| EPS (TTM) | 0.0034 EUR |
Data delayed at least 20 minutes, as of Feb 11 2026 15:23 GMT.
More ▼
Announcements
- Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
- Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS
- Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy
- Pharming Group reports preliminary 2025 revenues and announces Investor Day
- Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit
- Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
- Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London
- Pharming Group to report third quarter 2025 financial results and provide business update on November 6
- Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
- Pharming Group provides update on previously announced G&A expense reduction plan
More ▼
